Andere talen Avacta Group Plc

Aandelen

Vertraagde tijd London S.E. Andere beurzen 14:26:30 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
45,72 ^GBX	-2,20%		+3,13%	-60,61%

01/05	Avacta kiest Christina Coughlin als opvolger van lang zittende CEO	AN
30/04	VERDIENSTEN: Avacta omzet stijgt; Poolbeg verlies wordt kleiner; Digital 9 NAV daalt	AN

Avacta Group plc - Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group	01/05
Avacta picks Christina Coughlin to replace long-serving CEO	01/05
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down	30/04
Avacta Group CEO Steps Down; Successor Appointed	30/04
Avacta : Results for the Year Ended 31 December 2023	30/04
Avacta : Preliminary Results for the Year Ended 31 December 2023	30/04
Avacta : Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group	30/04
Avacta Group Plc Reports Earnings Results for the Full Year Ended December 31, 2023	30/04
Avacta Group plc Announces Chief Executive Officer Changes	30/04
Avacta : R&D Spotlight series – Episode 2	25/04
Avacta Group plc - Block Listing Application to AIM	24/04
Avacta Group plc - Notice of Results	24/04
First Tin updates Tellerhauser estimates	22/04
Avacta Therapeutics Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 at the AACR Annual Meeting Demonstrating Clinical Proof-of-Concept Showing Multiple Patient Responses	10/04
Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting	09/04
Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update	05/04
Avacta : Glossary	05/04
Avacta : Research and Development Spotlight Series – Episode 1	27/03
Avacta doses third patient in drug conjugate trial for tumour tissue	21/03
Avacta shareholders give AGM go-ahead to issue new shares	18/03

Geen resultaten voor deze zoekopdracht